NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present via a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 23, 2020:
Presentation Time: 11:30 a.m. ETA live webcast of the virtual fireside chat can be accessed by visiting a??News & Eventsa?? in the a??Investors & Newsa?? section on the Companya??s website at
www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Companya??s website following the conference.The Companya??s corporate presentation is posted to its website in the a??Investors & Newsa?? section under a??News & Eventsa??.About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc.A is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinsona??s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
